|
Pharmacotherapy Interventions |
|||||||||
| Medication |
Pop |
CG |
RA |
Num* |
TSL (days) |
Dose |
DT (days) |
Key Outcome Measures |
Article |
|
|
|||||||||
| Nortriptyline |
Senior |
Y |
Y-NE |
80/66 |
216–279 |
Steady-state plasma level: 50–120 ng/mL |
112 |
Depression (HAM-D); Grief (TRIG) |
Reynolds, Miller, et al, 1999** |
| Senior |
Y |
Y-NE |
27/27 |
210 (mean) |
Steady-state plasma level: 79.9+/-28.3 ng/mL Daily dose: 70.8+/-22.2 mg |
<180 |
Sleep (PSQI); Depression (HAM-D, BDI) |
Taylor, Reynolds, et al, 1999 |
|
| Senior |
Y |
NR |
30/24 |
276 |
Steady-state plasma level: 72.7 ng/mL Daily dose: 53.0 mg |
112 |
Sleep (PSQI) |
Pasternak, Reynolds, et al, 1994 |
|
| Senior |
N |
NA |
13/13 |
150–750 |
Daily dose: 49.2 mg |
9–184 |
Depression (HAM-D, BDI, BSI); Grief (TRIG, JGI); Sleep (PSQI) |
Pasternak, Reynolds, et al, 1991 |
|
| Nortriptyline and Paroxetine |
Adult |
N |
NA |
21/15 |
183–4158 |
PT Daily dose: 20–50 mg NT Daily dose: 50–160 mg |
120 |
Depression (HAM-D); Grief (ICG); Sleep (PSQI) |
Zygmont, Prigerson, et al, 1998 |
| Desipramine |
Adult |
N |
NA |
10/9 |
NR |
Daily dose: 75–150 mg |
28 |
Depression (HDRS, CGI, Raskin DS); Grief (Separation Distress) |
Jacobs, Nelson, et al, 1987 |
| Bupropion |
Adult |
N |
NA |
22/14 |
42–56 |
Daily dose: 150–300 mg |
56 |
Grief (TRIG, ICG); Depression (HAM-D) |
Zisook, Schuchter, et al, 2001 |
| Diazepam |
Senior |
Y |
Y |
35/30 |
<14 |
2 mg/pill, self-administered |
<42 |
Bereavement (BPQ) |
Warner, Metcalfe, et al, 2001 |
|
Notes: * All Ns are reported as (starting population of bereaved individuals/bereaved population completing all follow-ups), unless only study included only one assessment. ** Study also included psychotherapy condition. Legend: Pop, Target Population; CG, Control Group; RA, Random Assignment; Num, Number of subjects; TSL, Time Since Loss; DT, Duration of Trial; NA, Not Applicable; NR, Not Reported; UC, Unclear; Y, Yes; N, No; Y-NE, Randomization mentioned, but allocation method not explicitly stated; RS, Randomization Subverted. | |||||||||
Forte et al. BMC Palliative Care 2004 3:3 doi:10.1186/1472-684X-3-3 |
|||||||||